Strong Enrollment and Promising Strategy Propel Viking Therapeutics to ‘Buy’ Rating

Joseph Pantginis, an analyst from H.C. Wainwright, reiterated the Buy rating on Viking Therapeutics. The associated price target remains the same with $102.00.

Joseph Pantginis has given his Buy rating due to a combination of factors, including the strong enrollment completion of the VANQUISH-1 trial, which exceeded its target size ahead of schedule. This indicates a robust demand for Viking Therapeutics’ VK2735, particularly in its subcutaneous form for patients with obesity or overweight conditions.
Additionally, the promising strategy for oral VK2735, which aims to balance effective weight loss with manageable dosing and pill size, further supports the positive outlook. The upcoming end-of-Phase 2 FDA meeting and the potential for a favorable commercial position if Phase 3 data are consistent with current findings contribute to the stock’s potential upside.